MX2021007074A - Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso. - Google Patents

Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso.

Info

Publication number
MX2021007074A
MX2021007074A MX2021007074A MX2021007074A MX2021007074A MX 2021007074 A MX2021007074 A MX 2021007074A MX 2021007074 A MX2021007074 A MX 2021007074A MX 2021007074 A MX2021007074 A MX 2021007074A MX 2021007074 A MX2021007074 A MX 2021007074A
Authority
MX
Mexico
Prior art keywords
compositions
labyrinthin
methods
based peptides
cancer immunotherapies
Prior art date
Application number
MX2021007074A
Other languages
English (en)
Inventor
James A Radosevich
Michael Babich
Original Assignee
Labyrx Immunologic Therapeutics Usa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labyrx Immunologic Therapeutics Usa Ltd filed Critical Labyrx Immunologic Therapeutics Usa Ltd
Publication of MX2021007074A publication Critical patent/MX2021007074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen composiciones antigénicas que comprenden uno o más péptidos derivados de laberintina (labyrinthin). En alguna modalidad, cada péptido de la composición antigénica comprende un epítopo de célula T y/o un epítopo de célula B. En otros aspectos, la presente descripción proporciona, por ejemplo, composiciones de vacuna que comprenden una composición antigénica descrita en la presente, incluidos los kits, medicamentos y composiciones (tal como composiciones farmacéuticas y dosis unitarias) de las mismas. También se proporcionan métodos para usar las composiciones descritas en la presente, tal como métodos de tratamiento de las mismas y métodos de producción de anticuerpos, y composiciones de anticuerpos de las mismas, contra uno o más péptidos derivados de laberintina o una porción de los mismos.
MX2021007074A 2018-12-13 2019-12-13 Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso. MX2021007074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779377P 2018-12-13 2018-12-13
PCT/US2019/066264 WO2020123964A1 (en) 2018-12-13 2019-12-13 Labyrinthin-based peptides for cancer immunotherapies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021007074A true MX2021007074A (es) 2021-10-13

Family

ID=71077093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007074A MX2021007074A (es) 2018-12-13 2019-12-13 Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso.

Country Status (11)

Country Link
US (1) US20220409709A1 (es)
EP (1) EP3894432A4 (es)
JP (1) JP2022513913A (es)
KR (1) KR20210131995A (es)
CN (1) CN113412275A (es)
AU (1) AU2019397539A1 (es)
CA (1) CA3123396A1 (es)
IL (1) IL283933A (es)
MX (1) MX2021007074A (es)
TW (1) TW202039536A (es)
WO (1) WO2020123964A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
JP2009525047A (ja) * 2006-02-02 2009-07-09 ザ ユーエイビー リサーチ ファウンデイション 肺炎レンサ球菌表面タンパク質ｐｓｐａおよびｐｓｐｃの非−コイル保護領域
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
EP2607374A1 (en) * 2011-12-21 2013-06-26 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof

Also Published As

Publication number Publication date
JP2022513913A (ja) 2022-02-09
US20220409709A1 (en) 2022-12-29
CN113412275A (zh) 2021-09-17
CA3123396A1 (en) 2020-06-18
IL283933A (en) 2021-07-29
AU2019397539A1 (en) 2021-07-15
KR20210131995A (ko) 2021-11-03
EP3894432A4 (en) 2023-01-25
EP3894432A1 (en) 2021-10-20
WO2020123964A1 (en) 2020-06-18
TW202039536A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
MX2019002968A (es) Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MY185802A (en) Antibody formulation
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
MX340796B (es) Composiciones y procedimientos antigenicos del virus respiratorio sincitial.
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
MX2021005085A (es) Formulacion de anticuerpo.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
MX2021007047A (es) Formulaciones de anticuerpos.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)